Drug Profile
Research programme: fms-like tyrosine kinase 3 inhibitors - Antisoma/Johns Hopkins
Alternative Names: DCAMs - AntisomaLatest Information Update: 15 Jun 2011
Price :
$50
*
At a glance
- Originator Johns Hopkins University
- Developer Antisoma
- Class Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- Discontinued Autoimmune disorders